Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma

Next Previous
X
Search
Trial Profile

A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavorixafor (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors X4 Pharmaceuticals

    • Most Recent Events

    • 02 Jan 2019 Status changed from recruiting to completed.
    • 18 Apr 2018 As of September 15, 2017, 13 patients have been enrolled, and 11 have completed the study, according to results presented at the 109th Annual Meeting of the American Association for Cancer Research.
    • 18 Apr 2018 Results (n=13) assessing safety and tolerability of X4P-001 in combination with Keytruda (pembrolizumab) in patients with advanced melanoma, were presented at the 109th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top